Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
Rhea-AI Summary
Allogene (Nasdaq: ALLO) intends to sell $175 million of common stock in an underwritten public offering announced April 13, 2026, with a 30-day underwriter option to purchase up to $26.25 million additional shares. The offering is subject to market conditions and may not be completed.
Net proceeds are expected to fund general corporate purposes, including clinical trial and R&D expenses, general and administrative costs, and capital expenditures. Goldman Sachs, Jefferies and TD Cowen are joint book-running managers; TPG Capital BD is co-manager. Shares will be offered from a shelf registration declared effective April 25, 2024.
Positive
- Offering size of $175 million announced April 13, 2026
- Additional option for underwriters up to $26.25 million
- Proceeds earmarked for clinical trial and R&D spending
Negative
- Potential dilution to existing shareholders from primary share sale
- No assurance the offering will be completed or on proposed terms
- Market pressure possible if large share volume enters market
News Market Reaction – ALLO
In the Apr 14 session, ALLO declined 25.49%, reflecting a significant negative market reaction. Argus tracked a peak move of +55.9% during that session. Argus tracked a trough of -32.2% from its starting point during tracking. Our momentum scanner triggered 66 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.8x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Equity offering | Negative | +2.1% | Announced $110M common stock offering under shelf to fund AlloCAR T pipeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior common stock offering in May 2024 coincided with a modestly positive +2.07% move, indicating past equity raises were absorbed constructively.
Historically, Allogene’s only tagged offering event was a $110 million common stock raise in May 2024, which saw a +2.07% next-day move. Since then, company updates have focused on advancing its AlloCAR T pipeline and funding development. Today’s proposed $175 million offering again targets general corporate and R&D uses, fitting a pattern of tapping equity markets to support pivotal trials and broader platform expansion.
Key Terms
underwritten public offering financial
joint book-running managers financial
co-manager financial
shelf registration statement regulatory
prospectus supplement regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions,
Allogene expects to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses, and capital expenditures.
Goldman Sachs & Co. LLC, Jefferies and TD Cowen are acting as the joint book-running managers for the offering. TPG Capital BD, LLC is acting as co-manager for the offering.
The shares of common stock described above are being offered by Allogene pursuant to a shelf registration statement filed by Allogene with the Securities and Exchange Commission (SEC) that was declared effective on April 25, 2024. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by telephone at (877) 821-7388, or by emailing prospectus_department@jefferies.com; or from TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Allogene’s expectations with respect to the completion, timing and size of the proposed public offering, the use of proceeds from the offering and granting the underwriters a 30-day option to purchase additional shares. For such statements, Allogene claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Allogene’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Allogene’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, and other filings that Allogene may make from time to time with the SEC. These forward-looking statements represent Allogene’s judgment as of the time of this release. Allogene disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
